The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
|Articles|May 12, 2023
Supplements and Featured Publications
- Long-Term Safety and Efficacy of Esketamine in Patients With Treatment-Resistant Depression: A Review of Interim Results From the SUSTAIN-3 Trial
Long-Term Safety and Efficacy of Esketamine in Patients With Treatment-Resistant Depression: A Review of Interim Results From the SUSTAIN-3 Trial
Advertisement
This publication is sponsored by Janssen Pharmaceuticals, Inc.
The ongoing SUSTAIN-3 trial (NCT02782104) investigates the long-term safety and efficacy of individualized, intermittently dosed esketamine nasal spray used with an oral antidepressant in patients with treatment-resistant depression. This clinical brief reviews both the established short-term efficacy and safety profile of esketamine nasal spray and the study design and interim analysis results of the SUSTAIN-3 study.
Advertisement
Related to this article
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5